Efficacy of silvernanoparticles mouthwash and chlorhexidine mouthwash

COMPARATIVE EVALUATION OF THE EFFICACY OF SILVER NANOPARTICLES MOUTHWASH WITH CHLORHEXIDINE MOUTHWASH IN CHRONIC PERIODONTITIS PATIENTS. A CLINICAL MICROBIOLOGICAL STUDY

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/053193

Enrollment

Registered

2023-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Silver nanoparticle mouthwash: NANOLIFE MOUTHWASH,5 ml,2 times in a day for 14 days Control Intervention1: HEXIDINE MOUTHWASH: CHLOEXIDINE MOUTHWASH (0.12%), 5 ml , 2 times a day for 1

Eligibility

Inclusion criteria

Inclusion criteria: 1. Systemically healthy subjects with probing pocket depth of 1- 4 mm 2. Patients exhibited 1-2 mm of clinical attachment loss 3. Horizontal bone loss with no furcation involvement 4. Stage I periodontitis patients Demography related: 5.Age range of 18â??60 years old of any gender. 6.Patients willing to give written and informed consent before any study specific procedure. 7.Hemodynamically stable patients

Exclusion criteria

Exclusion criteria: 1.Patients requiring periodontal flap surgery 2.Recurrent history of periodontal infections and wearing orthodontic brackets. 3.Use of antibiotics in the past 3â??4 weeks 4.History of use of mouthwash within last month 5.Patient with acute necrotizing ulcerative gingivitis, acute herpetic gingivostomatitis, allergic gingivitis, gingivitis associated with skin diseases, gingivitis associated with endocrine-metabolic disturbances, gingivitis associated with hematologic-immunologic disturbances, gingival enlargement associated with medications, gingival tumors 6.Active Hepatitis B virus or Hepatitis C virus, HIV/AIDS 7.Subjects who having psychiatry/physical morbidity and cannot perform proper manual brushing 8.Individuals with known systemic disease 9.Smokers

Design outcomes

Primary

Measure	Time frame
1.To assess and compare the modified gingival index and plaque index in Group A, Group B and Group C at baseline, 7 days and 14 days. 2.To assess and compare the colony forming units (CFU) of E.coli in plaque samples atbaseline, 7 days and 14 days in GROUP A, GROUP B and GROUP C. 3.To assess and compare pocket depth reduction and clinical attachment levels in SRP group, silver nanoparticles mouthwash group and chlorhexidine mouthwashgroup at 3 months. Timepoint: 7 day 14 day 3 month	—

Measure

Time frame

1.To assess and compare the modified gingival index and plaque index in Group A, Group B and Group C at baseline, 7 days and 14 days. 2.To assess and compare the colony forming units (CFU) of E.coli in plaque samples atbaseline, 7 days and 14 days in GROUP A, GROUP B and GROUP C. 3.To assess and compare pocket depth reduction and clinical attachment levels in SRP group, silver nanoparticles mouthwash group and chlorhexidine mouthwashgroup at 3 months. Timepoint: 7 day 14 day 3 month

—

Secondary

Measure	Time frame
â?¢ To evaluate of the clinical effectiveness of silver nanoparticles mouthwash versus chlorhexidine mouthwash in different groups of age and gender.Timepoint: 7 day 14 day 3 month	—

Countries

India

Contacts

Public ContactDr Shivani Sachdeva

Rural Dental College; Pravara institute of medical sciences

dr.shivani19@gmail.com09730548805

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026